Russian tennis star Maria Sharapova has decided to utilise her time away from international tennis, due to a doping ban, by enrolling in the Harvard Business School.
Not sure how this happened but Hey Harvard! Can’t wait to start the program! 🎓📓 pic.twitter.com/EOoKYhaQli
— Maria Sharapova (@MariaSharapova) June 25, 2016
The 29-year-old tested positive for the controversial banned medication meldonium during January’s Australian Open.
If her appeal is unsuccessful the five-time Grand Slam champion will miss the Olympic Games in Rio in August while the earliest Grand Slam she could next enter is the French Open in 2018.
Sharapova blasted the ban as “unfairly harsh” in a statement on her Facebook page.
Sharapova, the world’s highest-paid female athlete, stunned the sporting world in March when she announced that she had tested positive for meldonium, a drug she said she had been taking for a decade to treat diabetes and low magnesium.
Sharapova has 35 WTA singles titles and has won all four of the sport’s grand slam titles.
Her career earnings amount to $36 million while her off-court earnings, according to Forbes, are around $200 million.
The story includes input from Reuters and AFP.